CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade IVERIC bio, Inc. - ISEE CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

IVERIC bio Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 8.95-39.72
Average Volume (10 days) 7.66M
Average Volume (3 months) 96.76M
Market Cap 5.43B
P/E Ratio -100.00K
Shares Outstanding 137.98M
Revenue N/A
EPS -1.76
Dividend (Yield %) N/A
Beta 1.07
Next Earnings Date Jul 24, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low

IVERIC bio, Inc. Events

Time (UTC) Country Event
Wednesday, November 1, 2023

Time (UTC)

12:30

Country

US

Event

Q3 2023 IVERIC bio Inc Earnings Release
Q3 2023 IVERIC bio Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0 0
Total Operating Expense 189.906 114.757 88.736 61.272 -59.651
Selling/General/Admin. Expenses, Total 72.894 29.689 25.952 21.628 23.612
Research & Development 117.012 85.068 62.784 39.644 41.737
Operating Income -189.906 -114.757 -88.736 -61.272 59.651
Interest Income (Expense), Net Non-Operating 2.264 0.245 0.5 2.151 2.389
Other, Net 0.062 -0.01 -0.006 0.151 -0.016
Net Income Before Taxes -185.211 -114.522 -88.242 -58.97 62.024
Net Income After Taxes -185.211 -114.522 -84.547 -58.859 63.087
Net Income Before Extra. Items -185.211 -114.522 -84.547 -58.859 63.087
Net Income -185.211 -114.522 -84.547 -58.859 63.087
Income Available to Common Excl. Extra. Items -185.211 -114.522 -84.547 -58.859 63.087
Income Available to Common Incl. Extra. Items -185.211 -114.522 -84.547 -58.859 63.087
Diluted Net Income -185.211 -114.522 -84.547 -58.859 63.087
Diluted Weighted Average Shares 121.037 101.866 74.185 42.224 37.088
Diluted EPS Excluding Extraordinary Items -1.5302 -1.12424 -1.13968 -1.39397 1.70101
Diluted Normalized EPS -1.54977 -1.12424 -1.13968 -1.39397 -0.48973
Total Extraordinary Items
Unusual Expense (Income) 0 0 -125
Gain (Loss) on Sale of Assets 2.369
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 73.841 62.971 42.512 49.753 34.67
Selling/General/Admin. Expenses, Total 31.758 27.13 17.545 16.106 12.113
Research & Development 42.083 35.841 24.967 33.647 22.557
Operating Income -73.841 -62.971 -42.512 -49.753 -34.67
Interest Income (Expense), Net Non-Operating 3.461 1.449 0.2 0.482 0.133
Other, Net -1.849 0.092 -0.039 0.008 0.001
Net Income Before Taxes -72.229 -59.061 -42.351 -49.263 -34.536
Net Income After Taxes -72.229 -59.061 -42.351 -49.263 -34.536
Net Income Before Extra. Items -72.229 -59.061 -42.351 -49.263 -34.536
Net Income -72.229 -59.061 -42.351 -49.263 -34.536
Income Available to Common Excl. Extra. Items -72.229 -59.061 -42.351 -49.263 -34.536
Income Available to Common Incl. Extra. Items -72.229 -59.061 -42.351 -49.263 -34.536
Diluted Net Income -72.229 -59.061 -42.351 -49.263 -34.536
Diluted Weighted Average Shares 137.087 125.414 120.277 119.687 118.755
Diluted EPS Excluding Extraordinary Items -0.52688 -0.47093 -0.35211 -0.4116 -0.29082
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.52688 -0.48982 -0.35211 -0.4116 -0.29082
Gain (Loss) on Sale of Assets 2.369
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 662.826 387.488 216.603 128.624 133.287
Cash and Short Term Investments 646.835 381.749 210.047 125.699 131.201
Cash & Equivalents 476.304 261.447 66.373 125.699 131.201
Short Term Investments 170.531 120.302 143.674
Total Receivables, Net 0 1.765 0.882 0
Accounts Receivable - Trade, Net
Prepaid Expenses 15.991 5.739 4.791 2.043 2.086
Total Assets 666.823 389.358 216.754 130.187 137.165
Property/Plant/Equipment, Total - Net 2.128 1.87 0.146 0.669 0.335
Property/Plant/Equipment, Total - Gross 3.259 2.863 1.1 1.476 1.345
Accumulated Depreciation, Total -1.131 -0.993 -0.954 -0.807 -1.01
Long Term Investments
Other Long Term Assets, Total 1.869 0 0.005 0.012 0.014
Total Current Liabilities 35.587 28.211 25.13 12.984 13.206
Payable/Accrued 22.843 12.856 12.792 5.629 5.869
Accrued Expenses 12.744 15.355 12.338 7.355 7.337
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total
Total Liabilities 132.166 28.83 25.191 12.984 13.206
Total Long Term Debt 96.568 0 0 0 0
Other Liabilities, Total 0.011 0.619 0.061 0
Total Equity 534.657 360.528 191.563 117.203 123.959
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.137 0.115 0.09 0.05 0.041
Additional Paid-In Capital 1399.56 1040.1 756.543 597.679 545.585
Retained Earnings (Accumulated Deficit) -864.806 -679.595 -565.073 -480.526 -421.667
Other Equity, Total -0.229 -0.09 0.003
Total Liabilities & Shareholders’ Equity 666.823 389.358 216.754 130.187 137.165
Total Common Shares Outstanding 136.64 115.277 90.1208 49.6271 41.3972
Note Receivable - Long Term 0 0.882 3.529
Long Term Debt 96.568
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 611.543 662.826 329.478 317.222 350.967
Cash and Short Term Investments 599.921 646.835 320.535 311.963 345.663
Cash & Equivalents 467.572 476.304 153.1 141.113 191.867
Short Term Investments 132.349 170.531 167.435 170.85 153.796
Total Receivables, Net 0
Prepaid Expenses 11.622 15.991 8.943 5.259 5.304
Total Assets 613.407 666.823 331.79 319.756 352.705
Property/Plant/Equipment, Total - Net 1.864 2.128 2.312 2.534 1.738
Other Long Term Assets, Total 0 1.869 0
Total Current Liabilities 39.374 35.587 24.588 26.479 19.166
Payable/Accrued 18.026 22.843 11.601 8.178 5.294
Accrued Expenses 21.348 12.744 12.987 18.301 13.872
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 136.361 132.166 72.264 26.81 19.551
Total Long Term Debt 96.987 96.568 47.649 0 0
Other Liabilities, Total 0 0.011 0.027 0.331 0.385
Total Equity 477.046 534.657 259.526 292.946 333.154
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.137 0.137 0.121 0.117 0.116
Additional Paid-In Capital 1414.04 1399.56 1065.55 1056.75 1047.56
Retained Earnings (Accumulated Deficit) -937.035 -864.806 -805.745 -763.394 -714.131
Other Equity, Total -0.099 -0.229 -0.395 -0.528 -0.394
Total Liabilities & Shareholders’ Equity 613.407 666.823 331.79 319.756 352.705
Total Common Shares Outstanding 137.25 136.64 120.573 116.874 115.974
Property/Plant/Equipment, Total - Gross 3.259
Accumulated Depreciation, Total -1.131
Long Term Debt 96.987 96.568 47.649
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -185.211 -114.522 -84.547 -58.859 63.087
Cash From Operating Activities -163.771 -98.559 -66.097 -48.49 -41.911
Cash From Operating Activities 0.138 0.039 0.143 0.162 0.183
Deferred Taxes 0 0
Non-Cash Items 26.019 12.427 8.785 9.115 -108.309
Cash Taxes Paid 0 1.765 3.327 1.893 2.467
Changes in Working Capital -4.717 3.497 9.522 1.092 3.128
Cash From Investing Activities -50.277 21.298 -143.81 0.15 0
Capital Expenditures -0.736 -0.361 0
Other Investing Cash Flow Items, Total -49.541 21.659 -143.81 0.15 0
Cash From Financing Activities 428.905 272.335 150.581 42.838 6.14
Financing Cash Flow Items
Issuance (Retirement) of Stock, Net 332.803 272.335 150.581 42.838 6.14
Net Change in Cash 214.857 195.074 -59.326 -5.502 -35.771
Issuance (Retirement) of Debt, Net 96.102
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -72.229 -185.211 -126.15 -83.799 -34.536
Cash From Operating Activities -50.593 -163.771 -114.537 -73.421 -37.512
Cash From Operating Activities 0.07 0.138 0.08 0.045 0.021
Non-Cash Items 11.029 26.019 18.952 12.314 5.686
Changes in Working Capital 10.537 -4.717 -7.419 -1.981 -8.683
Cash From Investing Activities 39.272 -50.277 -48.41 -51.794 -34.148
Other Investing Cash Flow Items, Total 39.505 -49.541 -47.97 -51.583 -34.032
Cash From Financing Activities 2.589 428.905 54.6 4.881 2.08
Issuance (Retirement) of Stock, Net 2.589 332.803 7.123 4.881 2.08
Net Change in Cash -8.732 214.857 -108.347 -120.334 -69.58
Cash Taxes Paid 0 0 0
Capital Expenditures -0.233 -0.736 -0.44 -0.211 -0.116
Issuance (Retirement) of Debt, Net 96.102 47.477
Cash Interest Paid 2.406

IVERIC bio, Inc. Company profile

About IVERIC bio Inc

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, IVERIC bio Inc revenues was not reported. Net loss increased 35% to $114.5M. Higher net loss reflects Reasearch and development increase of 34% to $78.5M (expense), General and administrative increase of 15% to $25M (expense), Stock-based Compensation in R&D increase of 57% to $6.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.14 to -$1.12.

Equity composition

Common Stock, $0.001 Par, 09/13, 30,110,817 issd., Insiders own approx. 74.76%

Industry: Biotechnology & Medical Research (NEC)

8 Sylvan Way
Suite 2372
PARSIPPANY
NEW JERSEY 07054
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

Oil - Crude

90.41 Price
+0.950% 1D Chg, %
Long position overnight fee 0.0353%
Short position overnight fee -0.0572%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
+0.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

BTC/USD

26,677.35 Price
+0.180% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

US100

14,765.80 Price
+0.600% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading